Lumos Pharma, Inc. (LUMO) entered a merger agreement on October 23, 2024, to be taken private by Double Point Ventures LLC through a tender offer valued at $27.65 million.
As part of the agreement, Double Point Ventures will acquire Lumos Pharma’s outstanding shares of common stock for $4.25 per share in cash, a 7.59% premium over the stock’s last close, plus one non-transferable, unsecured Contingent Value Right (CVR) per share.